Press release content from Globe Newswire. The AP news staff was not involved in its creation.
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the .
GW Pharmaceuticals plcApril 20, 2021 GMT
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –
– TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines
1
–
LONDON, April 20, 2021 (GLOBE NEWSWIRE) GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication
GW Pharmaceuticals plc: GW Pharmaceuticals receives European Commission approval for EPIDYOLEX (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
-
LONDON, April 20, 2021 (GLOBE NEWSWIRE) GW Pharmaceuticals plc (Nasdaq: GWPH) ( GW , the Company or the Group ), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe.
GW Pharmaceuticals plc
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe –
LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX
GW Pharmaceuticals plc: GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.